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Abstract
Rivaroxaban is an oral, direct Factor Xa inhibitor approved in the European Union and several other countries for the
prevention of venous thromboembolism in adult patients undergoing elective hip or knee replacement surgery and is in
advanced clinical development for the treatment of thromboembolic disorders. Its mechanism of action is antithrombin
independent and differs from that of other anticoagulants, such as warfarin (a vitamin K antagonist), enoxaparin (an indirect
thrombin/Factor Xa inhibitor) and dabigatran (a direct thrombin inhibitor). A blood coagulation computer model has been
developed, based on several published models and preclinical and clinical data. Unlike previous models, the current model
takes into account both the intrinsic and extrinsic pathways of the coagulation cascade, and possesses some unique
features, including a blood flow component and a portfolio of drug action mechanisms. This study aimed to use the model
to compare the mechanism of action of rivaroxaban with that of warfarin, and to evaluate the efficacy and safety of different
rivaroxaban doses with other anticoagulants included in the model. Rather than reproducing known standard clinical
measurements, such as the prothrombin time and activated partial thromboplastin time clotting tests, the anticoagulant
benchmarking was based on a simulation of physiologically plausible clotting scenarios. Compared with warfarin,
rivaroxaban showed a favourable sensitivity for tissue factor concentration inducing clotting, and a steep concentration–
effect relationship, rapidly flattening towards higher inhibitor concentrations, both suggesting a broad therapeutic window.
The predicted dosing window is highly accordant with the final dose recommendation based upon extensive clinical
studies.
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Introduction
The blood coagulation cascade is a complex process, involving
both an intrinsic and an extrinsic pathway (Figure 1) [1]. The
different classes of anticoagulant drugs currently on the market or
in clinical development target different factors within the
coagulation cascade (Figure 1). The most interesting new classes
of anticoagulants include the direct thrombin inhibitors and the
Factor Xa inhibitors (direct or indirect).
Rivaroxaban is an oral, direct Factor Xa inhibitor approved in
more than 100 countries worldwide, including the European
Union and Canada, for the prevention of venous thromboembo-
lism after elective hip or knee replacement surgery in adult
patients, and is in advanced clinical development for the treatment
of thromboembolic disorders. Rivaroxaban only targets one factor
within the coagulation cascade, Factor Xa, and its mechanism of
action is antithrombin (AT) independent [2,3]. This mechanism of
action is different from that of other anticoagulants that have been
or are currently used in clinical practice, such as warfarin (a
vitamin K antagonist) [4], enoxaparin (an indirect thrombin/
Factor Xa inhibitor) [5,6], ximelagatran (now withdrawn) [7] and
dabigatran (direct thrombin inhibitors) [8].
A computer model for blood coagulation has been developed,
based on several published models [9–14]. In contrast to these
previous models, the one presented here takes into account both
the intrinsic and extrinsic pathways of the coagulation cascade and
possesses some unique features that were not included in these
earlier models, such as a blood flow component and a portfolio of
drug action mechanisms based on their physicochemical proper-
ties and pharmacokinetic profiles. The aim of this study was to use
this model to evaluate the efficacy and safety of different doses of
rivaroxaban compared with other anticoagulants, thereby esti-
mating a therapeutic window for rivaroxaban.
The model was built to cover several aspects of the coagulation
cascade, including the extrinsic pathway (initiated with the
triggering of tissue factor [TF]), the intrinsic pathway (initiated
with activation of Factor XII [Factor XIIa]) and the common
pathways leading to fibrin generation via thrombin generation.
Additional features were also included: inhibition via the TF
pathway inhibitor or via AT, and the fact that in vivo coagulation is
affected by blood flow, which leads to an exchange of proteins
between the clot and the fresh blood pool. The action of calcium
ions (within membrane-bound enzyme complexes, e.g. the
prothrombinase complex) were indirectly included in the rate
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binding sites were directly included in the model kinetics. A
portfolio of drug action mechanisms and pharmacokinetic profiles
was also included in the model: rivaroxaban and DX-9065a (direct
Factor Xa inhibitors), warfarin, enoxaparin and ximelagatran.
The model was adjusted to accurately represent both preclinical
information, such as directly measured dissociation constants, and
clinical measurements such as the common clotting tests,
prothrombin time (PT) and activated partial thromboplastin time
(aPTT). Some additional aspects of the coagulation cascade will be
developed in further improvements to the model, including:
thrombocytes and their action; fibrinolysis and spatial thrombus
properties.
This computer model was used to assess the efficacy and safety
of rivaroxaban compared with that of other anticoagulants
included in the model, by using physiologically plausible clotting
scenarios with presumably high relevance for bleeding as well as
thrombosis events. The computer model was subsequently applied
to the modelling of the therapeutic window of rivaroxaban by
comparing the inhibitory effect of all anticoagulants in these
virtual clotting scenarios, which were not feasible with laboratory
in vitro test systems.
Methods
Structural properties of the model
The program package MoBiH (Bayer Technology Services,
Leverkusen, Germany) [15] was used as the software platform.
The structural properties of the model represent qualitative
knowledge about the coagulation processes. This is exemplified
by the cleavage and activation of prothrombin (Factor II) to
thrombin (Factor IIa) by Factor Xa. This reaction is included in
the model to take into account both the stoichiometric part:
Factor II?Factor IIa ð1Þ
and the kinetics part:
k16|Factor Xa|Factor II ð2Þ
(see: Appendix S1, Reaction R9)
Equation 1 represents the one-to-one (stoichiometric) conver-
sion of Factor II to Factor IIa (prothrombin to thrombin).
Equation 2 describes the kinetic law governing the rate of
conversion: it is proportional to the concentrations of Factor Xa,
Factor II, with k16 being the kinetic constant. Kinetic parameters
and initial conditions (concentrations) represent the quantitative
information about the coagulation system and take into account
the impact of the different study drugs (see: Appendix S2 and
Appendix S3). Kinetic equations are given according to standard
mass action law convention.
The coagulation model
Individual factors and interactions were classified using the well-
characterized extrinsic or intrinsic pathways, because the model
was constructed to represent the typical in vitro tests used for
investigating the extrinsic and intrinsic processes (PT and aPTT,
respectively) in one unified computational representation. Trans-
port reactions taking into account the blood flow were then
Figure 1. Targets for anticoagulant drugs in the coagulation pathway [57].
doi:10.1371/journal.pone.0017626.g001
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physiological in vivo setting.
The extrinsic core of the model was adapted from the model by
Hockin et al. [10] and consists of 32 reactions (see: Appendix S1,
reactions named with R and number). It covers all relevant
interactions and factors, from the triggering of the cascade by TF,
to Factor II (prothrombin) activation and Factor IIa (thrombin)
formation. The PT test best assesses coagulation activity in the
extrinsic pathway.
The intrinsic pathway was adapted from the model published
by Kogan et al. [11] and consists of the reactions listed in
Appendix S1 containing rate constants starting with ‘Kog’ (at the
end of the appendix). It covers all relevant interactions and factors
leading from Factor XIIa to Factor Xa. The aPTT test best
assesses coagulation activity in the intrinsic pathway.
Further model extensions were taken from the model developed
by Anand et al. [14]. A feedback loop for the activation of Factor
XI and a reaction representing the cleavage of fibrinogen (RI), also
introduced by Kogan et al. [11,16] and kinetic data taken from
Stevens et al. [16] were added to the original model to define two
independent thresholds for thrombus formation – one based on
Factor IIa and the other on the fibrinogen cleavage product
(named ‘Ia’ in the model and being used as a representation of
fibrin formation) concentration, respectively.
The protein C/S system and the coagulation factor adsorption
reactions to lipids were developed on the basis of the model
published by Bungay et al. [9] and by Kuharsky and Fogelson [13].
In addition to reactions published by these authors, the protein C/S
model part was extended by us with further reactions that reflect
additional inactivation paths (see: Appendix S1, reaction names
starting with ‘RBu’ containing extra letters appended to the
number). The integration of phospholipid vesicles led to a set of
adsorption reactions (see: Appendix S1, reaction names starting
with ‘Rad’), but we also needed to duplicate several reactions to
account for the option that several of the components might react
either when bound to phospholipids or when being dissolved (see:
Appendix S1, reaction names of the scheme ‘R’ number ‘d’). The
species ‘PhosphoLipid’ represents protein-binding sites on phos-
pholipid vesicles. Bungay et al. use an average of 100 phospholipid
molecules per site, but our model was set to 333 molecules per site,
being of the same size as published experimental values [17].
Additional coagulation factor inhibition reactions were intro-
duced based on published rate constants [18–23]. The rate
constant for the inhibitor AT (ATIII), which was in the upper
Table 1. Regimens for rivaroxaban, warfarin, ximelagatran, DX-9065a and enoxaparin included in the model.
Rivaroxaban Warfarin Ximelagatran DX-9065a Enoxaparin
Dose (mg)
Plasma
level (mg/l)
Dose
(INR)
Plasma
level
Dose
(mg)
Plasma
level (mM) Dose
Plasma
level
(mg/l)
Dose
(mg s.c.)
Plasma level
(mg/l)
5O D C max 60.98 1.5 24 BD Cmax 0.21 IV infusion 100 20 OD Cmax 1.79
Cmean 24.280 2.0 Cmean 0.12 200 Cmean 0.76
Ctrough 4.27 2.5 Ctrough 0.04 Ctrough 0.19
5B D C max 75.97 3.0 60 BD Cmax 0.52 40 OD Cmax 3.69
Cmean 42.83 3.5 Cmean 0.31 Cmean 1.57
Ctrough 16.36 4.0 Ctrough 0.12 Ctrough 0.40
10 OD Cmax 121.97 30 BD Cmax 2.74
Cmean 48.56 Cmean 1.95
Ctrough 8.54 Ctrough 0.95
10 BD Cmax 151.9 105 OD (1.5 mg/kg) Cmax 12.8
Cmean 85.66 Cmean 5.47
Ctrough 32.73 Ctrough 1.40
20 OD Cmax 195.15 70 BD (1 mg/kg) Cmax 10.79
Cmean 77.69 Cmean 7.67
Ctrough 13.66 Ctrough 3.74
20 BD Cmax 243.10
Cmean 137.06
Ctrough 52.37
53 OD Cmax 387.86
Cmean 154.42
Ctrough 27.15
53 BD Cmax 483.17
Cmean 272.42
Ctrough 104.08
53 mg OD/BD doses (although not used in clinical studies) were simulated to double exposure (Cmean) of 20 mg OD/BD, taking into account the less than dose-
proportional increase in exposure due to reduced absorption, observed at high doses [3,26]. A control without any drugs was also run in the model. BD, twice daily;
Cmax, maximum drug concentration; Cmean, average drug concentration; Ctrough, minimum drug concentration; INR, international normalized ratio; IV, intravenous; OD,
once daily; s.c., subcutaneous.
doi:10.1371/journal.pone.0017626.t001
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et al. [10], was reduced in our model. The action of von
Willebrand factor was introduced based on the scheme and rate
constants published by Saenko et al. [24].
Drug action
All study drugs were modelled by a representation of their
anticoagulant properties using what was known from published
information. Values for direct kinetic constants (kon and koff)w e r eu s e d
when available. When no direct experimental kinetic data for
individual biochemical reactions were available, values were deter-
mined numerically by fitting the model behaviour to indirect
measurements using PT and aPTT values versus drug concentrations.
A broad set of regimens (doses and schedules) was simulated, both with
constant drug levels and dynamic pharmacokinetic profiles (Table 1).
Rivaroxaban. Rivaroxaban acts via complexation to free
Factor Xa and to the prothrombinase complex (Factor Xa and
activated Factor V [Factor Va]; Table 2) [2]. Experimental kinetic
data were available for the reaction of complexation to Factor Xa
[25]. Kinetic constants were calculated and fitted into the model
based on measured Ki values [2] and experimental PT–
rivaroxaban plasma concentration relationships [26]. The
binding of rivaroxaban to proteins was modelled as a
complexation/decomplexation reaction (RBay3), and kinetic
constants were calculated and fitted into the model based on the
values of measured fraction of unbound drug and PT versus
Table 2. Modelling of drug action.
Reaction name Stoichiometry Kinetics
Rivaroxaban action
RBay1 Bay59_7939+XaRBay59_7939_Xa Bay59_7939*Xa*kBay1-Bay59_7939_Xa*kBay1*kBay_Ki_Xa
RBay1s Bay59_7939+Xa_lipidRBay59_7939_Xa_lipid Bay59_7939*Xa_lipid*kBay1-
Bay59_7939_Xa_lipid*kBay1*kBay_Ki_Xa
RBay2 Bay59_7939+Xa_Va_lipidRBay59_7939_Xa_Va_lipid Bay59_7939*Xa_Va_lipid*kBay3-
Bay59_7939_Xa_Va_lipid*kBay3*kBay_Ki_XaVa
RBay3 Bay59_7939_BoundRBay59_7939 kBay_fu_on*kBay_fu*Bay59_7939_Bound-
kBay_fu_on*Albumin_Factor*Bay59_7939
RBay4 Bay59_7939_Xa+ATIIIRBay59_7939_Xa_ATIII kBay5*Bay59_7939_Xa*ATIII
RBay5 Bay59_7939+Xa_ATIIIRBay59_7939_Xa_ATIII kBay6*Bay59_7939*Xa_ATIII-
kBay6*kBay_Ki_XaATIII*Bay59_7939_Xa_ATIII
DX-9065a action
RDx1 DX9065a+XaRDX9065a_Xa kDx1*DX9065a*Xa-kDx2*DX9065a_Xa
RDx1s DX9065a+Xa_lipidRDX9065a_Xa_lipid kDx1*DX9065a*Xa_lipid-kDx2*DX9065a_Xa_lipid
RDx2 DX9065a+Xa_Va_lipidRDX9065a_Xa_Va_lipid kDx3*DX9065a*Xa_Va_lipid-kDx4*DX9065a_Xa_Va_lipid
RDx3 DX9065a_Xa+ATIIIRDX9065a_Xa_ATIII kDx5*DX9065a_Xa*ATIII
RDx4 DX9065aRDx9065a_Bound kDx_fu_on*Albumin_Factor*Dx9065a-
kDx_fu_on*kDx_fu*DX9065a_Bound
RDx5 DX9065a+Xa_ATIIIRDX9065a_Xa_ATIII kDx6*DX9065a*Xa_ATIII-kDx7*DX9065a_Xa_ATIII
(Xi)Melagatran action
RXi1 Xim+IIaRIIa_Xim kXim1*IIa*Xim-kXim2*IIa_Xim
RXi2 Xim+mIIaRmIIa_Xim kXim3*mIIa*Xim-kXim4*mIIa_Xim
RXi3 Xim+IIa_TmRIIa_Tm_Xim kXim5*IIa_Tm*Xim-kXim6*IIa_Tm_Xim
RXi4 XimRXim_Bound kXim_fu_on*Albumin_Factor*Xim-kXim_fu_on*kXim_fu*Xim_Bound
Enoxaparin action
RHep1 HepRHep_Bound kHep_fu_on*Albumin_Factor*Hep-
kHep_fu_on*kHep_fu*Hep_Bound
RHep2 ATIII+HepRATIIIa kHep_ATIII_on*ATIII*Hep-kHep_ATIII_on*kHep_Ki_ATIII*ATIIIa
RHep3 Xa+ATIIIaRXa_ATIII+Hep kHep_Xa_ATIIIa*Xa*ATIIIa
RHep4 Xa_lipid+ATIIIaRXa_ATIII+PhosphoLipid+Hep kHep_Xa_ATIIIa*Xa_lipid*ATIIIa
RHep5 Xa_Va_lipid+ATIIIaRXa_ATIII+Hep+Va_lipid kHep_XaVa_ATIIIa*Xa_Va_lipid*ATIIIa
RHep6 IIa+ATIIIaRIIa_ATIII+Hep kHep_IIa_ATIIIa*IIa*ATIIIa
RHep7 mIIa+ATIIIaRmIIa_ATIII+Hep kHep_IIa_ATIIIa*mIIa*ATIIIa
RHep8 ATIIIa+IXaRIXa_ATIII+Hep kHep_IXa_ATIIIa*IXa*ATIIIa
RHep9 ATIIIa+IXa_lipidRIXa_ATIII+PhosphoLipid+Hep kHep_IXa_ATIIIa*IXa_lipid*ATIIIa
RHep10 XIa+ATIIIaRXIa_ATIII+Hep kHep_XIa_ATIIIa*XIa*ATIIIa
RHep11 XIa_lipid+ATIIIaRXIa_ATIII+PhosphoLipid+Hep kHep_XIa_ATIIIa*XIa_lipid*ATIIIa
Va, IIa, IXa, Xa and XIa denote activated coagulation factors. ATIII, antithrombin; BAY59-7939, rivaroxaban; fu, fraction unbound; Hep, heparin (here parameterized as
enoxaparin); on, kon, association rate constant; mIIa, meizothrombin; Tm, thrombomodulin; Xim, ximelagatran active metabolite (melagatran).
doi:10.1371/journal.pone.0017626.t002
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used to model protein binding for all other study drugs, with some
variations to take the different mechanisms of action into account.
DX-9065a. The method used to fit DX-9065a into the model
wassimilar to that used for rivaroxaban,because the two drugshave
a similar mechanism of action [27]. Because DX-9065a–Factor Xa
complexescanbind FactorVa, this reactionwas added to the model
(RDx3;Table 2).Allkinetic constantsand thestructure ofthemodel
(pharmacological values) were found in the literature [28–32].
Ximelagatran. The binding reactions of melagatran (the
active metabolite of ximelagatran) to Factor IIa, meizothrombin
(mIIa), and the thrombin–thrombomodulin complex were added
into the model (RXi1 to RXi4; Table 2). All kinetic constants and
the structure of the model (mechanistic mode of action) were found
in the literature [33–38].
Enoxaparin. The complexation of enoxaparin to AT, and the
subsequent reactions of this complex with Factor Xa, the Factor
Xa–Factor Va complex (prothrombinase), Factor IIa, mIIa, Factor
IXa and Factor XIa were added into the model (Table 2, RHep1 to
RHep11). The major inhibitoryeffect is on Factor Xa (free and lipid
bound), which is reflected by the highest rate constant. The model
takes into account the dissociation of enoxaparin after any of these
targets is bound to activated AT, and enoxaparin is released,
allowing it to activate another molecule of AT.
Warfarin. The action of warfarin was not modelled explicitly,
but represented by a shiftin initial conditions (starting concentrations)
for vitamin K-dependent Factors II, VII, IX and X, as well as
proteins C and S based on published data [39]. To reach a given
therapeutic international normalized ratio (INR), each vitamin K-
dependent Factor concentration was simultaneously reduced to the
required percentage of the normal value.
Blood flow
The model had to take into account the fact that in vivo
coagulation is not only triggered by weak TF and Factor XIIa
concentrations and propagated by the coagulation cascade, but is also
affected byblood flow and the resulting exchangeofproteinsbetween
the clotting region (and its surrounding area, named ‘thromb’) and
thefreshblood poolthat generallyincludesnon-activatedcoagulation
factors (Figure 2). The model described so far was coupled with an
infinite pool of plasma (named ‘blood’) to represent the loss of
activated factors and the supply of non-activated factors due to blood
flow and diffusion (Figure 2). We used an approach similar to
Kuharsky and Fogelson [13] and assumed a linear flow parameter,
which was identical for all transported species, to describe the mass
exchange. This resulted in transport reactions for each species X in
the model (see: Appendix S1 and Appendix S2) of the form:
a|D| X blood{X thromb ðÞ
The only species not transported are those bound to immobile
tissue or to the thrombus (i.e. TF and all its formed complexes with
Figure 2. Modelling of blood flow. The top equation represents the initial condition where the concentration of each species cj is the same for
the coagulation zone ‘thromb’ and the reservoir ‘blood’. The first element of the bottom equation (‘coagulation kinetics’) represents the coagulation
processes (i.e. the biochemical kinetics of the model), whereas the second element (‘coupling’) represents the flowing conditions. a, general coupling
constant, as a function of blood flow and geometry (size of vessels); cj, concentration of coagulation factor; Dj, diffusion–convection coefficient; F,
blood coagulation cascade model coefficient.
doi:10.1371/journal.pone.0017626.g002
Table 3. In vivo coagulation scenarios included in the model.
Scenario
Tissue factor
concentration (M)
Factor XIIa
concentration (M)
Extrinsic strong 10
211 0
Extrinsic weak 10
214 0
Intrinsic strong 0 10
211
Intrinsic weak 0 10
214
doi:10.1371/journal.pone.0017626.t003
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determined by a general coupling constant (a), which controls the
overall strength of the coupling, and a Factor-dependent diffusion–
convection constant, termed D (set to 5610
27 cm
2/s, averaged
from the more complex hydrodynamic approach of Anand et al.
(Table 3) [14]. When a is zero, the flow model is equal to the static
model; increasing a represents an increase of the blood flow. The
lowest exchange rate (i.e. the critical value of a [acrit]), which
suppresses a coagulation event for a given trigger scenario, was
calculated, and comparisons of the different acrit values for the
Figure 3. Benchmarking of anticoagulants based on thresholds for blood flow-mediated washout using physiologically plausible
trigger concentrations. The dashed line and dots and the dotted line and the diamonds indicate the spread of the threshold for blood flow- and
diffusion-mediated washout of a clot formation (acrit, seconds; Methods) within the therapeutic concentration range (difference between Ctrough and
Cmax); acrit at Cmean is indicated by the solid line and crosses. The strong extrinsic trigger (TF 10
211 mol/l, seconds; Table 3) is considered as safety
relevant (A). The (red) shaded area indicates safety-relevant prolongation of clotting times above the effect of warfarin titrated to an INR of 3, which is
used as a safety reference. All therapies above the level of this therapy are considered safe. The other three triggers (B: Factor XIIa 10
211 mol/l; C: TF
10
214 mol/l; D: 10
214 mol/l) are considered as efficacy relevant. The effect of warfarin titrated to an INR of 1.5 is used as an efficacy reference and all
therapies reaching inhibition above the level of this therapy, i.e. acrit values below the reference level (green shaded area) are considered efficacious.
BD, twice daily; Cmax, maximum concentration; Cmean, mean concentration; Ctrough, minimum concentration; INR, international normalized ratio; IV,
intravenous; OD, once daily; TF, tissue factor.
doi:10.1371/journal.pone.0017626.g003
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and dosing schedules (Results, Figure 3). However, there were no
means to determine acrit directly or correlate it to an experimen-
tally accessible value. Furthermore, it is important to note that this
model only focused on the onset of coagulation (i.e. that
fibrinolysis was not included in this model).
Initial conditions
The initial concentrations for all modelled coagulation factors
and other proteins are given in Appendix S2. Depending on the
coagulation scenario (in vitro or in vivo), individual factors not listed
in Appendix S2, such as TF or Factor XIIa/Factor XIa (i.e. the
triggers), were set to values other than zero, as for the values given
in Table 3 or described below for PT and aPTT.
Kinetic parameters
Kinetic parameters, including kinetic and diffusion constants,
are given in Appendix S3. These constants are independent of the
simulated coagulation scenario, except for the general flow
coupling constant a, the dilution factor (see below), and the
albumin–factor coupling constant, which describes the dilution of
albumin and affects the unbound fraction of the different study
drugs.
Figure 4. Implementation of PT into in vitro coagulation
scenarios. Simulation of a PT scenario, thrombin and fibrin generation.
PT, prothrombin time.
doi:10.1371/journal.pone.0017626.g004
Figure 5. Simulation of coagulation factor variations and comparison with published experimental data. (A) published PT INR data
from Fisher Diagnostics 1999 [40] and with (B) published aPTT data from Kappert 2002 [41]. Reagents used in aPTT reference studies: PathromtinH SL
(SL; Behringwerke AG, Marburg, Germany) and Behring Coagulation Time (BCT). aPTT, activated partial thromboplastin time; INR, international
normalized ratio; PT, prothrombin time.
doi:10.1371/journal.pone.0017626.g005
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Dilution of plasma by a coagulation reagent was defined as
reduced concentrations of all plasma proteins and factors, as well
as added drugs, or as adjusted effective concentrations for surface-
bound factors (e.g. TF). Initial plasma concentrations of inhibitors
(study drugs) were calculated based on pharmacokinetic data.
Prothrombin time. All concentrations given in Appendix S2
werereducedtoafactorofone-thirdtoaccountforinvitrodilution,in
order to reproduce the procedures generally used for the PT test.
The tests require that an aliquot of plasma be mixed with an aliquot
of coagulation test reagent containing trigger(s), phospholipids,
calcium ions and buffer. To initiate a PT test, TF 4 nM
concentrations were used, together with preactivated 1% of Factor
V taken from [10]. PT was defined as the time when the fibrin
concentration reached 100 nM for the first time (Figure 4), meaning
that after dilution in the assay, more than 4% of the physiological
amount of fibrinogen (7 mM, see Appendix S2) had been activated
for clot formation. This was found to be the starting point of a
massivecleavageoffibrinogeninthemodel.TheINRwascalculated
by simply dividing PT with study drug by PT without study drug,
thus assuming an ISI exponent of 1 for our simulated PT reagent.
The dependence of the INR on individual coagulation factor
variance was simulated and compared withpublished data[40].The
quality of the fit (Figure 5A) was used as validation for the model.
Activated partial thromboplastin time. All concentrations
given in Appendix S2 were reduced to a factor of one-third to
account for in vitro dilution and to reproduce the procedures
generally used for the aPTT test. To initiate an aPTT test, 2.2 nM
Factor XIa and 50 nM Factor XIIa concentrations were used,
together with preactivated 1% of Factor V taken from [10]. The
coagulation factor variations were simulated and compared with
published data [40,41]. The quality of the fit (Figure 5B) was used
as validation for the model.
Implementation of coagulation scenarios – in vivo
scenarios
To mimic in vivo conditions relevant to bleeding risks under
anticoagulant therapy and relevant to thrombosis, four trigger
scenarios were constructed (Table 3). All four scenarios are
considered to be more closely related to physiological conditions
than classical ex vivo laboratory tests, where trigger concentrations
many orders of magnitude higher than those occurring in vivo have
to be used for practical reasons.
As a safety-relevant strong trigger, a high TF concentration
(10
211 mol/l) representing contact with subendothelial tissue was
chosen. Prolongation of clotting times under this scenario was
interpreted as an increased bleeding risk. To investigate efficacy,
three triggers (a low TF concentration, 10
214 mol/l, and two
Factor XIIa concentrations, 10
211 and 10
214 mol/l) were
separately applied, which represent typical situations where
massive clotting should not occur, simulating plasma not in
contact with subendothelial tissue. In such scenarios, a significant
clotting would raise the risk of thrombosis. These three triggers are
interpreted as a complement to the bleeding scenario.
Besides the direct calculation of clotting times under all four
trigger scenarios, acrit values were also determined for all these
scenarios with and without anticoagulants, the results being used
for benchmarking of therapies.
Figure 7. Comparison of simulated with measured INR values.
One control group (Control) without medication and three patient
groups: mechanical (Mec) or biological (Bio) heart valve replacement
with different co-medications (acetylsalicylic acid [ASA] or warfarin
[War]) at different target INRs with model predictions of INRs [47].
Simulated INR values were based on measurements of the mean
concentrations of Factors II, VII, X, protein C and protein S resulting
from therapy. Factor IX was set to the average concentration of the
measured factors. INR, international normalized ratio.
doi:10.1371/journal.pone.0017626.g007
Figure 8. Simulation of thrombus inhibition with rivaroxaban
and warfarin. Rivaroxaban concentrations at 20 mg once daily: Cmax
251 ng/ml, Ctrough 30 ng/ml. The width of the rivaroxaban curve reflects
the Ctrough to Cmax concentration range and the width of the warfarin
curve reflects the typically used INR range. Cmax, maximum concentra-
tion; Ctrough, minimum concentration; INR, international normalized
ratio; OD, once daily; TF, tissue factor.
doi:10.1371/journal.pone.0017626.g008
Figure 6. PT and aPTT dependent on plasma concentration of anticoagulant drugs. (A) rivaroxaban (experimental data from internal
studies); (B) DX-9065a (experimental data from the literature [30,31,41]; and (C) ximelagatran (experimental data for PT and aPTT from the literature
[36,37]. aPTT, activated partial thromboplastin time; INR, international normalized ratio; PT, prothrombin time.
doi:10.1371/journal.pone.0017626.g006
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Drug action mechanism models of rivaroxaban and other
anticoagulants
Comparisons were made between experimental concentration–
response profiles (data taken from the literature [30,31,36,37,42]
or from in-house studies conducted with rivaroxaban) and
simulation results for all study drugs. Plots for PT and aPTT that
are dependent on plasma concentrations of rivaroxaban, DX-
9065a and ximelagatran in Figures 6A, 6B and 6C, respectively,
compare the experimental data with simulated plots for these three
drugs [30,31,36,37,42].
Enoxaparin concentrations in blood are determined in anti-
Factor Xa units because it is not a homogenous substance but a
mixture of different oligomers [38]. However, using the reported
value of 100 units per mg enoxaparin and an average molecular
weight of 4500 g/mol, approximate molar concentrations re-
quired for modelling can be obtained. PT and aPTT values as a
function of plasma concentrations are reported to be not
meaningful within the therapeutic concentration range [38], thus
being less suited for a model calibration. Anti-Factor Xa values
alone on the other hand are not sufficient to validate inactivation
kinetics. However, several publications reporting kinetic constants
are available [27,43–45]. Averages of these published in vitro values
were used in our model (Appendix S3, parameters starting with
kHep). Simulated PT and aPTT values increased only marginally
within therapeutic concentrations (data not shown).
Typical subcutaneous doses are between 20 mg once daily (od)
and 30 mg twice daily (bid) for prevention, and 1.5 mg/kg od or
1.0 mg/kg bid for acute therapy. We obtained corresponding
plasma concentrations from the manufacturer’s data sheets [38]
and from the public files of the registration agencies [46].
Unavailable concentrations were taken or extrapolated from in-
house measured enoxaparin pharmacokinetic curves. Table 1 lists
the concentrations used in our simulations.
Warfarin validation results are shown in Figure 7. The resulting
prolongations of the simulated PT values, depicted as INRs, were
in good agreement with published data [47]. Variations in
experimental data were primarily caused by individual variations
in factor concentrations, which are frequent with warfarin therapy,
and less by experimental error. Simulations were conducted for
the mean concentrations and, therefore, the results presented are
close to the actual mean INR data.
Applications of the model to clinical studies
Efficacy and safety compared with
warfarin. Rivaroxaban 20 mg od was compared with
warfarin (INR 1.5–3.0). Clotting times were measured as a
function of TF concentrations (Figure 8). At low TF
concentrations, the therapeutic INR window for warfarin has a
large overlap with the concentration window of the direct Factor
Xa inhibitor. By contrast, warfarin shows a stronger effect (i.e.
prolongation) on clotting times at higher TF concentrations than
the direct Factor Xa inhibitor rivaroxaban. In other words, the
mechanism of direct Factor Xa inhibition shows a steeper
dependency on TF trigger concentrations than vitamin K-
dependent inhibition of the coagulation systems. There is a clear
tendency to higher potency at low (i.e. thrombosis relevant) TF
concentrations and a lower potency at high TF concentrations
where anticoagulant effects could lead to bleeding.
Figure 9. Effect of rivaroxaban exposure on thrombin peak height. This graph shows the effect of increasing concentration of rivaroxaban
on thrombin peak height for a 5610
212 mol/l tissue factor trigger (dilution 2:3, 4 mM phospholipid, corresponding to an in silico thrombin generation
assay). To compare this with warfarin therapy, the corresponding values for INRs (1.5–4.0) are marked by vertical lines. The ranges for Cmax,C mean and
Ctrough reflect experimental rivaroxaban values found in dose-finding studies [48,50,55]. The simulated thrombin peak reduction is in the range of
therapeutically used INRs. BD, twice daily; Cmax, maximum concentration; Cmean, mean concentration; Ctrough, minimum concentration; INR,
international normalized ratio; OD, once daily.
doi:10.1371/journal.pone.0017626.g009
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achieve effects similar to warfarin therapy, titrated to different INR
values, were then calculated. Figure 9 shows peak concentrations of
Factor IIa obtained for a trigger scenario with 5610
212 mol/l TF,
(between the value of the extrinsic strong and weak triggers of
Table 3), and increasing rivaroxaban concentrations. The concen-
tration–effect curve shows a steep slope at low rivaroxaban
concentrations and levels off at concentrations above 150 mg/l.
According to this simulated scenario, this type of concentration–effect
relationship appears optimal for a broad therapeutic window. Both
the under-dosing and over-dosing risks are minimized because low
concentrations in the order of the Ctrough concentrations of Table 1
already reach significant efficacy levels, and variance at high
concentrations result in minimal reduction of the thrombin peak.
Dose-finding studies. The therapeutic window of rivarox-
aban was estimated by comparing rivaroxaban with ximelagatran,
Figure 10. Benchmarking of anticoagulants based on clotting times using physiologically plausible trigger concentrations. Error bars
show the spread of the clotting time within the therapeutic concentration range (difference between Ctrough and Cmax); clotting time at Cmean was
used for the main bar. The strong extrinsic trigger (TF 10
211 mol/l, seconds; Table 3) is considered as safety relevant (A). The (red) shaded area
indicates safety-relevant prolongation of clotting times above the effect of warfarin titrated to an INR of 3, which is used as a safety reference. All
therapies below the level of this therapy are considered safe. The other three triggers (B: Factor XIIa 10
211 mol/l; C: TF 10
214 mol/l; D: 10
214 mol/l)
are considered as efficacy relevant. The effect of warfarin titrated to an INR of 1.5 is used as an efficacy reference and all therapies reaching inhibition
above the level of this therapy (green shaded area) are considered efficacious. BD, twice daily; Cmax, maximum concentration; Cmean, mean
concentration; Ctrough, minimum concentration; INR, international normalized ratio; i.v., intravenous; OD, once daily, TF, tissue factor.
doi:10.1371/journal.pone.0017626.g010
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simulated and ranked for their effect on clotting time and acrit
with all triggers from the panel of physiologically plausible intrinsic
and extrinsic activations (Methods, Table 3). Typical doses for all
drugs were obtained after reviewing the literature. Figure 10 shows
the ranking of clotting times for all scenarios tested. For safety
assessment,the warfarin effectat anINRof3 wasusedasa reference
(upper threshold, red shaded area). For efficacy assessment, the
warfarin effect at an INR of 1.5 was used (lower threshold, green
shaded area). Using this (relative) measure, all rivaroxaban therapies
up to a dose of 20 mg bid are considered safe. Depending on the
efficacy scenario, daily doses of rivaroxaban above 5 mg appear to
be efficacious, with a daily dose of 20 mg reaching the efficacy
window in all three scenarios. Similar results were obtained with the
calculation of the acrit levels; daily doses of rivaroxaban between
5 mg and 40 mg appear to be safe and efficacious, with a possible
optimal dose of approximately 20 mg per day.
Discussion
The blood coagulation modelling presented in this paper allows
robust simulation of clinically relevant blood coagulation tests and
of in silico experiments that simulate flowing blood. The effects of
coagulation inhibitors acting upon coagulation factors can be
easily simulated using the graphical user interface MoBi. In
combination with experimental or simulated pharmacokinetic
data, therapeutic ranges for the drugs included in the model can
be evaluated and efficacy and safety limits can be determined.
The comparative analysis of the mechanism of direct Factor Xa
inhibition (rivaroxaban) showed a dependency on TF trigger
strength favourable to the vitamin K-dependent inhibition of the
coagulation system (Figure 8). At low trigger concentrations
assumed to be relevant for thrombosis prevention, the potency of
both mechanisms of action is similar, but at high trigger
concentrations, relevant for bleeding risk assessment, the effect
of direct inhibition is smaller. The concentration–effect curve of
rivaroxaban (Figure 9) shows a pronounced convex shape. The
increase of inhibition at low inhibitor concentrations is much
steeper than at high concentrations. Together with the TF
concentration dependency, this result supports the assumption of
a broad therapeutic range for direct Factor Xa inhibition.
The therapeutic window for rivaroxaban found by simulating
and ranking a broad portfolio of anticoagulants and scenarios was
a total daily dose between 5 mg and 40 mg (Figures 3 and 10).
Within this window, direct Factor Xa inhibition with rivaroxaban
compares well with other currently used or developed anticoag-
ulant therapies and consistently outperforms vitamin K-dependent
inhibition (warfarin). A 20 mg od dose yielded favourable
coagulation results, i.e. the safety margin of an INR 3 warfarin
therapy was not exceeded, and efficacy was better than an INR 1.5
therapy (see Figures 3 and 10). Dose-finding, phase IIb studies of
rivaroxaban for the prevention of venous thromboembolism in
patients undergoing total hip and knee replacement showed that
5–20 mg total daily doses had efficacy and safety similar to that of
enoxaparin, thereby demonstrating a wide therapeutic window for
rivaroxaban [48,49].
After another phase II study investigating the once-daily dosing
of rivaroxaban in patients undergoing total hip replacement [50],
the 10 mg od dose was considered to provide the optimal balance
between efficacy and safety. It was selected for further develop-
ment in the phase III RECORD programme, which investigated
the prevention of venous thromboembolism after total hip or total
knee replacement [51–54].
After two dose-ranging phase II studies for the treatment of
venous thromboembolism [55,56], a starting dose of 15 mg bid
followed by a 20 mg od maintenance dose of rivaroxaban was
selected for phase III studies in this indication. These doses are
within the therapeutic window of 5–50 mg determined by the
present computer model, thereby confirming its usefulness and
quantitative accuracy. Potential applications in modelling include
other aspects of coagulation, such as medication switch or the
combination of antithrombotic therapies (e.g. anticoagulant plus
platelet inhibitors) in the therapy of acute coronary syndrome.
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